Related Experiment Video

Updated: May 24, 2026

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

Complex medium supplements optimized for the reduction of animal-derived components in vaccine production media

James F Babcock1, Karen A Benedict1, Amanda L Perlman1

  • 1Sheffield Center for Cell Culture Technology, Sheffield Bio-Science, A Kerry Group Business, Ithaca, NY USA.

BMC Proceedings
|March 1, 2012
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

Related Concept Videos

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...